Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-HX02
- Development stage
- Unknown
- Lead developer
- Hexin Pharmaceutical Technology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-HX02 is a therapeutic radiopharmaceutical developed by Hexin Suzhou Pharmaceutical Technology for the treatment of advanced solid tumors. It consists of the beta-emitting radioisotope Lutetium-177 ($^{177}$Lu) conjugated to a high-affinity ligand (HX02) that specifically targets Fibroblast Activation Protein (FAP). FAP is a cell-surface serine protease that is highly overexpressed on cancer-associated fibroblasts (CAFs) within the stroma of various epithelial cancers, including pancreatic, colorectal, and breast cancers, while showing minimal expression in healthy adult tissues. Upon intravenous administration, 177Lu-HX02 selectively accumulates in the tumor microenvironment by binding to FAP-expressing cells. The localized emission of beta particles from the Lutetium-177 payload induces double-stranded DNA breaks and subsequent apoptosis in both the stromal fibroblasts and adjacent malignant cells via the bystander effect, thereby disrupting the tumor-supportive stroma and directly eliminating tumor cells.
- Other names
- Lutetium (177Lu) HX02177Lu-HX02 injection
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 177Lu-HX02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-HX02.